Ethoss Regeneration Ltd has received further national acclaim in the UK, being Highly Commended at the Lloyds Bank British Business Excellence Awards in the Exporter of the Year category at a glittering ceremony in London.
Building on receiving the prestigious Queens Award in 2021, this recognition caps off a fantastic year for EthOss and is a significant achievement for the company which now trades in over 50 countries around the world.
The Lloyds Bank British Business Excellence Awards are a major business award ceremony in the UK, with businesses from across the country competing. These awards “recognise and celebrate the resilience, innovation and creativity of British business” – more information can be found here (https://britishbusinessexcellenceawards.co.uk/).
Managing Director of EthOss Regeneration, Dr Paul Harrison, was delighted to see EthOss receive this achievement:
“2021 has been a fantastic year for EthOss and to receive further national recognition, after winning the Queens Award, is a great feeling. We have to thank all of our distributors around the world for their hard work in helping us get this far.
“The Lloyds Bank British Business Excellence Awards is one of the biggest events in the UK industry calendar. To be on the same platform as major UK companies being recognised for their successes shows how far EthOss has come, but also gives us encouragement to keep growing throughout 2022 and beyond.”
EthOss was founded in 2013 in West Yorkshire, by a world-renowned dental surgeon,- Dr Peter Fairbairn and a highly experienced biomaterial product development specialist, Dr Paul Harrison.
Together, the pair set out to create a product that would disrupt the dental bone grafting market, with the result being the company’s flagship product – EthOss® – a synthetic biomaterial used during dental implant surgery to encourage new bone to grow and support the implant.
Until then, this procedure had been done using a material containing animal product – usually bone harvested from cows, pigs and horses. The company’s aim is to grow a more ethical approach to dental implantology worldwide.